

EMERGING IMPACT BOND FUND (EIBF)

INVESTING IN INCLUSIVE DEVELOPMENT

MANAGER'S COMMENT

PERFORMANCE EIBF A/C - USD Cumulated Performance



No new investments were made during the month under review. Through its portfolio, the Fund finances 8,541 end clients, 47% of which are women and 30% of which live in rural areas.

MARKET COMMENT

Through the data on financial institutions available in the industry benchmark index SYM50, we have taken a look back at the trends in the MSME financing industry during 2017. Doing so, we saw that the MSME market experienced its strongest growth since 2013, with total assets growing on average by 21% (as compared to 10% in 2016 and 7% in 2015). Portfolio quality remained very stable with PAR30 at 5.2% in 2017 vs 5.0% in 2016. The gross portfolio yield decreased from on average 27% in 2016 to 25% in 2017, illustrating both an increased competition and improved financial inclusion. Due to the lower yield and relatively stable funding costs, the net interest margin decreased to 16% in 2017.

At the same time, overall profitability improved, with RoA of 2.2% (vs 1.9% in 2016) and RoE of 11.4% (vs 9%), signs both of an increased average loan size and improved productivity. Despite significant regional disparity, we thus note that the industry continued to do well in 2017.

- Libor 3 Month Cumulated Performance 104 103.5 103 102.5 102 101.5 101 100.5 100 99.5 16 Jan 18 Dec 17 Jan 17 Apr 17 May 17 Jul 17 Jun 17 Aug 17 Sep 17 Oct 17 **Nov 17**

HISTORICAL NET PERFORMANCE (%)

eb

٩ar

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
2018	0.23	-	-	-	-	-	-	-	-	-	-	-	0.23
2017	-0.09	0.26	0.73	0.51	0.21	0.31	0.45	-0.03	0.46	0.18	0.27	0.19	3.50
2016	-	-	-	-	-	-	-	-	-	-	-	-0.12	-0.12

A/C - USD

1 0 3 6.10

0.23%

SHARE CLASS PERF. Share Value Monthly

Dec

Year-to-date	0.23%
Annualized *	3.09%
Since Inception	3.61%
Best Month	0.73%
Worst Month	-0.12%
* Since inception	

FUND STATISTICS

Sharpe Ratio	2.22
Annualized Volatility	0.93%
Modified Duration	1.70
3-month US Libor Rate	1.77%

FUND FACTS

Net Asset Value	USDm 9.5
Investment Portfolio	USDm 7.7
Cash & Liquidities	USDm 1.9
Average Investment	USDm 0.4
Weighted Asset Maturity	20.9 months
Number of Countries	20
Number of Investees	23

LATEST INVESTMENTS	USD
Sovereign Bond , Hungary	0.2m
Sovereign Bond , Slovenia	0.5m
Sovereign Bond , Serbia	0.2m
BDF, Nicaragua	0.3m
Abaco, Peru	0.2m

IMPACT MEASUREMENT

THEMES	
Microfinance	31.8%
SME finance	23.8%
Housing finance	10.4%
Household finance	9.2%
Other	24.8%

SECTORS

SECTORS	
Agriculture	11.2%
Production	3.8%
Trade	26.0%
Services	11.6%
Other	47.4%


KEY INDICATORS

8,541 clients (est.) 47% women 30% rural 14,509 average financing size (USD)

* Excluding bonds issued by International Financial Institutions (IFIs) and Sovereign Bonds




FUND COMPOSITION ASSET CLASS




Promissory Notes ** Sovereign Bonds


PORTFOLIO ANALYSIS REGION BREAKDOWN (%)



REMAINING MATURITY BREAKDOWN




CREDIT RISK BREAKDOWN Current Portfolio Credit Risk: BBB




Source: Internal Symbiotics Methodoloay


INVESTEE TYPE



TOP 10 - COUNTRY BREAKDOWN (%)




CURRENCY BREAKDOWN



*All local currency investments are hedged.

COUNTRY RISK BREAKDOWN

Current Portfolio Country Risk: BBB-



LEGAL DISCLAIMER

The fund is domiciled in Luxembourg and has not been approved for distribution to non-qualified investors in or from Switzerland by the Swiss Financial Market Supervisory Authority (FINMA) pursuant to the Swiss Collective Investment Schemes Act of 23 June 2006 (the "CISA") and its implementing regulations. Accordingly, the fund offered hereby may only be offered and this document may only be distributed in or from Switzerland to qualified investors (as such term is defined in the CISA and its implementing regulations). This document and any other materials relating to the fund may only be used by those qualified investors to whom it has been handed out in connection with the offer described herein. It may not be copied, used by, distributed or made available to any other person. Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance data do not take account of the commissions and costs incurred on the issue and redemption of units. (ACEIS Bank, Paris, succursale de Nyon/Suisse, whose registered office is at Route de Signy 35, CH-1260 Nyon, Switzerland acts as the Swiss Representative Agent and the Swiss Paying Agent of the fund (the "Representative"). Only the latest version of the fund's prospectus, regulations and annual reports may be relied upon as fund the basis for investment decisions. These documents are available free of charges at the Representative's offices. The place of jurisdiction of the Representative is Switzerland. Symbiotics SA, Rue de la Synagogue 31, 1204 Geneva, Switzerland; Phone: +41 (0)22 338 15 40; www.symbioticsgroup.com; info@symbioticsgroup.com | Factsheet #502

Past performance should not be taken as an indication or guarantee of future performance and no representation or warranty, expressed or implied, is made by Symbiotics SA regarding future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units.